Bulgaria Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Bulgaria Breast Cancer Therapeutics Market Analysis

$ 3999

The Bulgaria breast cancer therapeutics market is expected to grow from $xx Bn in 2022 to $xx Bn in 2030 with a CAGR of xx% for the year 2022-2030 due to the advancements in breast cancer clinical trials in Bulgaria. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the major companies in Bulgaria's breast cancer therapeutics market are Kendy Pharma, Clenbuterol, and Roche.

ID: IN10BGPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Bulgaria AUTHOR: Parul Choudhary

Buy Now

Bulgaria Breast Cancer Therapeutics Market Executive Analysis

The Bulgaria breast cancer therapeutics market size is at around $xx Bn in 2022 and is projected to reach $xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period. In Bulgaria, the total cost of national healthcare in 2022 was a record-breaking $3.5 Bn. The budget for pharmaceuticals in Bulgaria is the highest at $888 Mn. Despite low per capita spending on health, out-of-pocket costs are the highest in the European Union and account for a sizable portion of GDP. The majority of health spending is typically allocated to medications and inpatient care, with very few funds set out for long-term care and prevention. The Bulgarian Ministry of Health (MoH) is in charge of overseeing the whole healthcare system, creating national health policy, drafting health laws, implementing programs to improve population health, and managing the budget and finances. 28 Regional Health Boards carry out national health policies through their operations.

Each year in Bulgaria, 1285 of the 3885 women who are diagnosed with breast cancer passed away from the disease. 18.4% of breast cancer patients under the age of 40 had a BRCA1 mutation, compared to 11.2% of patients diagnosed at a later age, and 4% of these patients had a BRCA2 mutation, versus 6.5% of patients diagnosed at a later age. In patients with a positive family history, 26.8% had a mutation, while 14.4% of women with a negative family history did.

According to a review in Bulgaria, single-dose irradiation and an exclusive radiotherapy approach were evaluated in patients with early breast cancer when Intraoperative Radiotherapy (IORT) was employed as a treatment option. Single-fraction high-dose radiation treatment is provided directly to the tumor or tumor bed during IORT as a single local Radiation Therapy (RT) or selective radiation boost. The advantages of IORT include an expanded therapeutic window, a constrained window for the repopulation of the residual tumor cells, and the potential for repeat radiation in the event of cancer recurrence. With this approach, a larger dose is administered, which enhances the immune response in both the nearby and potentially distant unirradiated tumoral volume, producing various radiobiological effects.

Market Dynamics

Market Growth Drivers

The development of novel trial designs for the early and late phase testing of monoclonal antibodies, as well as the rapid improvements in cancer research, are some of the factors that are anticipated to drive the expansion of the Bulgaria breast cancer therapeutics market in terms of revenue throughout the forecast period.

Market Restraints

Lack of access to modern therapeutics and expensive medical care are two of the major barriers to Bulgaria's breast cancer therapeutics market expansion. Due to insufficient healthcare infrastructure and reimbursement regulations, the growth of the breast cancer therapeutics market in Bulgaria may be slowed down.

Competitive Landscape

Key Players

Huvepharma (BGR)
Biovet (BGR)
Kendy Pharma (BGR)
Clenbuterol (BGR)
Roche
Novartis A
Pfizer
Celgene
Sanofi

Healthcare Policies and Regulatory Landscape

The compulsory health insurance system run by the Bulgarian Health Insurance Fund (BHIF) provides the majority of funding for the country's healthcare system. The government pays payments on behalf of individuals who are exempt, such as the old, the unemployed, and dependents, while the Fund receives contributions from the working population. The BHIF in Bulgaria offers coverage for breast cancer therapies. Additionally, the BHIF pays for some diagnostic procedures including mammograms and biopsies as well as the cost of medicines for breast cancer patients. The BHIF also pays for people with breast cancer to receive physiotherapy and rehabilitation services. The Bulgarian reimbursement system is based on a set of fixed costs for each surgery and therapy. Prior to submitting a claim to the BHIF for reimbursement, patients are obliged to pay the full cost of their treatment upfront. After reviewing the claim, the BHIF will decide how much should be paid to the patient. Some expensive and newer treatments might not be fully covered, and patients could need to foot some of the bill themselves. The number of consultations or treatments that the BHIF will pay for may also be limited.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.